Spectranetics (ticker: SPNC, exchange: NASDAQ Global Market (.O))
News Release -
Spectranetics CLiRpath Excimer Laser Catheters Among Top 10 Innovations in Podiatry Today
COLORADO SPRINGS, Colo., Aug. 8 /PRNewswire-FirstCall/ -- Spectranetics
Corporation (Nasdaq: SPNC) announced today the Company's CLiRpath(R) Excimer
Laser Catheter was featured in the August 2005 edition of Podiatry Today. The
article highlighted the trade publication's annual roundup of 10 current and
emerging innovations that may prove beneficial to podiatrists and their
patients. The feature article included detail on the use and benefits of the
Spectranetics CLiRpath excimer laser catheters for treating artery blockages
in the leg, and providing greater flexibility for the interventionalist and
podiatrist to avoid amputation due to peripheral vascular disease and critical
limb ischemia (CLI).
"Podiatrists are an extremely important referral source to CliRpath users,
and our public relations initiatives and podiatry outreach programs continue
to build an awareness of the advantages of early diagnosis and minimally
invasive treatment of CLI with our CLiRpath excimer laser catheters," said
John G. Schulte, president and chief executive officer of Spectranetics. "We
are delighted to be included among the Top 10 innovations by Podiatry Today.
This is the latest of several recent news articles highlighting the advantages
of treating peripheral vascular disease with our CLiRpath excimer laser
catheters and the life-changing outcomes to patients."
Quoting David G. Armstrong, DPM, Ph.D., a member of the National Board of
Directors of the American Diabetes Association, the article states, "The laser
blasts through obstructions to restore blood flow and also provides an
opportunity to traverse the site with a guidewire that can balloon the
More information on this and other recent articles and news segments
featuring Spectranetics' CLiRpath excimer laser catheters can be found on the
Company's website at www.spectranetics.com.
CLiRpath Excimer Laser Catheters are indicated for use in the endovascular
treatment of symptomatic infrainguinal lower extremity vascular disease where
total obstructions cannot be crossed with standard guide wires.
About Podiatry Today
Podiatry Today is a source for informative, how-to clinical articles and
practice management features for podiatrists. The magazine also offers the
latest news affecting the profession and an array of regular columns, ranging
from "Diabetes Watch" and "Surgical Pearls" to "Managed Care Insider."
Spectranetics is a medical device company that develops, manufactures and
markets single-use medical devices used in minimally invasive surgical
procedures within the cardiovascular system in conjunction with its
proprietary excimer laser system. Its CVX-300(R) excimer laser is the only
system approved by the FDA for multiple cardiovascular procedures, including
coronary atherectomy, and the removal of problematic pacemaker and
defibrillator leads. Nearly all of the company's FDA-approved and
investigational applications have received Communautes Europeennes (CE) mark
registration for marketing within Europe. In April 2004 Spectranetics
obtained 510(k) clearance from the FDA for the laser-based treatment of
patients suffering from total occlusions (blockages) in their leg arteries
that are not crossable with a guide wire.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements are based on current assumptions that
involve risks and uncertainties that could cause actual outcomes and results
to differ materially. These risks and uncertainties may include increasing
price and product competition, increased pressure on expense levels resulting
from expanded marketing and clinical activities, uncertain success of the
Company's strategic direction, dependence on new product development,
intellectual property claims of third parties, availability of inventory from
suppliers, the receipt of FDA approval to market new products or applications
and the timeliness of any approvals, the potential size of market
opportunities associated with new products, market acceptance of new products
or applications, product defects, price volatility due to the initiation or
cessation of coverage, or changes in ratings, by securities analysts. For a
further list and description of such risks and uncertainties that could cause
the actual results, performance or achievements of the Company to be
materially different from any anticipated results, performance or
achievements, please see the Company's previously filed SEC reports.
Spectranetics disclaims any intention or obligation to update or revise any
financial projections or forward-looking statements, whether as a result of
new information, future events or otherwise.
Spectranetics and CVX-300 are registered trademarks of The Spectranetics
Guy Childs, Chief Financial Officer
INVESTOR & MEDIA CONTACTS:
Lippert/Heilshorn & Associates, Inc.
Bruce Voss or Zachary Bryant
SOURCE Spectranetics Corporation